Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Y Feng

Showing results (91-100 of 460) with videos related to

Pageof 46
Sort By:
Cancer Research|November 6, 2021
Loss of Long Noncoding RNA <i>NXTAR</i> in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide ResistanceRuchi Ghildiyal, Mithila Sawant, Arun Renganathan, et al.
European Urology|July 18, 2024
Meta-analysis of Individual Patient-level Data for a Multimodal Artificial Intelligence Biomarker in High-risk Prostate Cancer: Results from Six NRG/RTOG Phase 3 Randomized TrialsDaniel E Spratt, Vinnie Y T Liu, Angela Y Jia, et al.
Advances in Radiation Oncology|July 18, 2022
Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 TrialKevin Shee, Claire M de la Calle, Albert J Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02Alan Pollack, James J Dignam, Dayssy A Diaz, et al.
Brachytherapy|May 14, 2017
External beam radiation therapy with or without low-dose-rate brachytherapy: Analysis of favorable and unfavorable intermediate-risk prostate cancer patientsAhmed E Abugharib, Robert T Dess, Payal D Soni, et al.
European Urology|May 26, 2015
Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical ProstatectomyWilliam C Jackson, Matthew J Schipper, Skyler B Johnson, et al.
International Journal of Radiation Oncology, Biology, Physics|January 3, 2012
Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancerKlaudia U Hunter, Felix Y Feng, Kent A Griffith, et al.
Urology|April 1, 2019
Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage RadiotherapyLauren Boreta, Adam J Gadzinski, Susan Y Wu, et al.
European Urology|January 3, 2016
Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate CancerRohit Mehra, Aaron M Udager, Thomas U Ahearn, et al.
European Urology Focus|July 21, 2017
Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer OutcomesDaniel E Spratt, Yu-Wei Chen, Brandon A Mahal, et al.
Pageof 46

Showing results (91-100 of 460) with videos related to

Sort By:
Pageof 46
Cancer Research|November 6, 2021
Loss of Long Noncoding RNA <i>NXTAR</i> in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide ResistanceRuchi Ghildiyal, Mithila Sawant, Arun Renganathan, et al.
European Urology|July 18, 2024
Meta-analysis of Individual Patient-level Data for a Multimodal Artificial Intelligence Biomarker in High-risk Prostate Cancer: Results from Six NRG/RTOG Phase 3 Randomized TrialsDaniel E Spratt, Vinnie Y T Liu, Angela Y Jia, et al.
Advances in Radiation Oncology|July 18, 2022
Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 TrialKevin Shee, Claire M de la Calle, Albert J Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02Alan Pollack, James J Dignam, Dayssy A Diaz, et al.
Brachytherapy|May 14, 2017
External beam radiation therapy with or without low-dose-rate brachytherapy: Analysis of favorable and unfavorable intermediate-risk prostate cancer patientsAhmed E Abugharib, Robert T Dess, Payal D Soni, et al.
European Urology|May 26, 2015
Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical ProstatectomyWilliam C Jackson, Matthew J Schipper, Skyler B Johnson, et al.
International Journal of Radiation Oncology, Biology, Physics|January 3, 2012
Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancerKlaudia U Hunter, Felix Y Feng, Kent A Griffith, et al.
Urology|April 1, 2019
Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage RadiotherapyLauren Boreta, Adam J Gadzinski, Susan Y Wu, et al.
European Urology|January 3, 2016
Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate CancerRohit Mehra, Aaron M Udager, Thomas U Ahearn, et al.
European Urology Focus|July 21, 2017
Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer OutcomesDaniel E Spratt, Yu-Wei Chen, Brandon A Mahal, et al.
Pageof 46